CONCOMITANT USE OF STRONG CYP3A4 INHIBITORS (E.G., KETOCONAZOLE, ITRACONAZOLE, CLARITHROMYCIN, ATAZANAVIR, INDINAVIR, NEFAZODONE, NELFINAVIR, RITONAVIR, SAQUINAVIR, TELITHROMYCIN, AND VORICONAZOLE) SHOULD BE AVOIDED DUE TO THE POTENTIAL FOR AN INCREASE IN DM1 EXPOSURE AND TOXICITY.